Double progression-free survival with PARP inhibitor as first-line maintenance therapy for ovarian cancer

Clovis Oncology announced today that its PARP inhibitor Rubraca (rucaparib) has achieved positive results in a Phase 3 clinical trial as first-line maintenance therapy

Ovarian cancer is the eighth leading cause of cancer death in women worldwide

Rubraca is an oral small molecule PARP1, 2, 3 inhibitor

In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, patients with newly diagnosed ovarian cancer received Rubraca monotherapy or placebo after receiving first-line chemotherapy and achieving remission

Across all randomized patient populations, median PFS was 20.

In the HRD-positive subgroup of patients, Rubraca reduced the risk of disease progression or death by 53% (HR=0.

An exploratory endpoint was also assessed in a subgroup of HRD-negative patients, in which Rubraca reduced the risk of disease progression or death by 35% (HR=0.

References:

[1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.